214 related articles for article (PubMed ID: 28571114)
1. Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.
Diekstra MH; Fritsch A; Kanefendt F; Swen JJ; Moes D; Sörgel F; Kinzig M; Stelzer C; Schindele D; Gauler T; Hauser S; Houtsma D; Roessler M; Moritz B; Mross K; Bergmann L; Oosterwijk E; Kiemeney LA; Guchelaar HJ; Jaehde U
CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):604-613. PubMed ID: 28571114
[TBL] [Abstract][Full Text] [Related]
2. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
[TBL] [Abstract][Full Text] [Related]
3. Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.
Beuselinck B; Lambrechts D; Van Brussel T; Wolter P; Cardinaels N; Joniau S; Lerut E; Karadimou A; Couchy G; Sebe P; Ravaud A; Zerbib M; Caty A; Paridaens R; Schöffski P; Verkarre V; Berger J; Patard JJ; Zucman-Rossi J; Oudard S
Acta Oncol; 2014 Oct; 53(10):1413-22. PubMed ID: 24874929
[TBL] [Abstract][Full Text] [Related]
4. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
[TBL] [Abstract][Full Text] [Related]
5. BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen.
Chae JW; Teo YL; Ho HK; Lee J; Back HM; Yun HY; Karlsson MO; Kwon KI; Chan A
Cancer Chemother Pharmacol; 2016 Sep; 78(3):623-32. PubMed ID: 27485537
[TBL] [Abstract][Full Text] [Related]
6. Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study.
Cabel L; Blanchet B; Thomas-Schoemann A; Huillard O; Bellesoeur A; Cessot A; Giroux J; Boudou-Rouquette P; Coriat R; Vidal M; Saidu NEB; Golmard L; Alexandre J; Goldwasser F
Fundam Clin Pharmacol; 2018 Feb; 32(1):98-107. PubMed ID: 29055166
[TBL] [Abstract][Full Text] [Related]
7. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.
Garcia-Donas J; Esteban E; Leandro-García LJ; Castellano DE; González del Alba A; Climent MA; Arranz JA; Gallardo E; Puente J; Bellmunt J; Mellado B; Martínez E; Moreno F; Font A; Robledo M; Rodríguez-Antona C
Lancet Oncol; 2011 Nov; 12(12):1143-50. PubMed ID: 22015057
[TBL] [Abstract][Full Text] [Related]
8. Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.
Narjoz C; Cessot A; Thomas-Schoemann A; Golmard JL; Huillard O; Boudou-Rouquette P; Behouche A; Taieb F; Durand JP; Dauphin A; Coriat R; Vidal M; Tod M; Alexandre J; Loriot MA; Goldwasser F; Blanchet B
Invest New Drugs; 2015 Feb; 33(1):257-68. PubMed ID: 25344452
[TBL] [Abstract][Full Text] [Related]
9. Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
Harmon CS; DePrimo SE; Figlin RA; Hudes GR; Hutson TE; Michaelson MD; Négrier S; Kim ST; Huang X; Williams JA; Eisen T; Motzer RJ
Cancer Chemother Pharmacol; 2014 Jan; 73(1):151-61. PubMed ID: 24220935
[TBL] [Abstract][Full Text] [Related]
10. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacokinetics.
Mizuno T; Fukudo M; Terada T; Kamba T; Nakamura E; Ogawa O; Inui K; Katsura T
Drug Metab Pharmacokinet; 2012; 27(6):631-9. PubMed ID: 22673043
[TBL] [Abstract][Full Text] [Related]
11. Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients.
Teo YL; Wee HL; Chue XP; Chau NM; Tan MH; Kanesvaran R; Wee HL; Ho HK; Chan A
Pharmacogenomics J; 2016 Feb; 16(1):47-53. PubMed ID: 25778465
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Adams VR; Leggas M
Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers.
Lindauer A; Di Gion P; Kanefendt F; Tomalik-Scharte D; Kinzig M; Rodamer M; Dodos F; Sörgel F; Fuhr U; Jaehde U
Clin Pharmacol Ther; 2010 May; 87(5):601-8. PubMed ID: 20376000
[TBL] [Abstract][Full Text] [Related]
14. Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662.
Diekstra MH; Klümpen HJ; Lolkema MP; Yu H; Kloth JS; Gelderblom H; van Schaik RH; Gurney H; Swen JJ; Huitema AD; Steeghs N; Mathijssen RH
Clin Pharmacol Ther; 2014 Jul; 96(1):81-9. PubMed ID: 24566734
[TBL] [Abstract][Full Text] [Related]
15. The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma.
Mizuno T; Fukudo M; Fukuda T; Terada T; Dong M; Kamba T; Yamasaki T; Ogawa O; Katsura T; Inui K; Vinks AA; Matsubara K
Ther Drug Monit; 2014 Jun; 36(3):310-6. PubMed ID: 24825438
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor.
Khosravan R; Motzer RJ; Fumagalli E; Rini BI
Clin Pharmacokinet; 2016 Oct; 55(10):1251-1269. PubMed ID: 27154065
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib-induced severe toxicities in a Japanese patient with the ABCG2 421 AA genotype.
Miura Y; Imamura CK; Fukunaga K; Katsuyama Y; Suyama K; Okaneya T; Mushiroda T; Ando Y; Takano T; Tanigawara Y
BMC Cancer; 2014 Dec; 14():964. PubMed ID: 25515134
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.
Yuasa T; Takahashi S; Hatake K; Yonese J; Fukui I
Cancer Sci; 2011 Nov; 102(11):1949-57. PubMed ID: 21812860
[TBL] [Abstract][Full Text] [Related]
19. Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.
van der Zanden LFM; Vermeulen SH; Oskarsdottir A; Maurits JSF; Diekstra MHM; Ambert V; Cambon-Thomsen A; Castellano D; Fritsch A; Garcia Donas J; Guarch Troyas R; Guchelaar HJ; Hartmann A; Hulsbergen-van de Kaa C; Jaehde U; Junker K; Martinez-Cardus A; Masson G; Oosterwijk-Wakka J; Radu MT; Rafnar T; Rodriguez-Antona C; Roessler M; Ruijtenbeek R; Stefansson K; Warren A; Wessels L; Eisen T; Kiemeney LALM; Oosterwijk E
Urol Oncol; 2017 Aug; 35(8):529.e9-529.e16. PubMed ID: 28385611
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]